Repatha® CV Outcomes Study: Adverse events and laboratory test results in a long-term study2,3

Repatha® Outcomes study adverse events Repatha® Outcomes study adverse events
  • The study profile was similar between Repatha®-treated patients with post-baseline LDL-C < 25 mg/dL compared with Repatha®-treated patients with higher post-baseline LDL-C (LDL-C ≥ 40 mg/dL) although not a randomized comparison3

  • In EBBINGHAUS, a substudy of 1,974 patients enrolled in the Outcomes trial, Repatha was non-inferior to placebo on selected cognitive function domains as assessed with the use of neuropsychological function tests over a median follow-up of 19 months1

*The total numbers of patients were 8,337 in the Repatha® group and 8,339 in the placebo group, because patients with prevalent diabetes at the start of the trial were excluded.2